SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the
Date of Report (Date of earliest event reported): March 9, 2004
Date of Filing: March 12, 2004
Lynx Therapeutics, Inc.
Delaware
(State or other jurisdiction of incorporation)
| 0-22570 (Commission File No.) |
94-3161073 (IRS Employer Identification No.) |
25861 Industrial Blvd.
Hayward, California 94545
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (510) 670-9300
| Item 5. Other Events | ||||||||
| Item 7. Financial Statements and Exhibits | ||||||||
| SIGNATURE | ||||||||
| INDEX TO EXHIBITS | ||||||||
| EXHIBIT 10.44 | ||||||||
| EXHIBIT 10.45 | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events
On March 9, 2004, Lynx Therapeutics, Inc. (the “Company”) completed a $4 million private placement of common stock and warrants to purchase common stock (the “financing”). The financing included the sale of 788,235 newly issued shares of common stock at a purchase price of $5.10 per share and the issuance of warrants to purchase 181,295 shares of common stock at an exercise price of $6.25 per share. The Company has agreed to file with the SEC a resale registration statement relating to the issued common stock and the common stock issuable upon exercise of the warrants. Forms of the transaction documents effecting the financing are attached as Exhibits 10.44 and 10.45. A press release announcing the financing is attached as Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits
(c) Exhibits
| 10.44 | Securities Purchase Agreement by and among the Company and the investors listed therein. | |||
| 10.45 | Form of Warrant issued by the Company in favor of each investor. | |||
| 99.1 | Press Release, dated March 10, 2004, entitled “Lynx Completes $4 Million Private Equity Financing.” | |||
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Lynx Therapeutics, Inc. | ||||
Dated:
March 12, 2004
|
By: | /s/ Kevin P. Corcoran | ||
| Kevin P. Corcoran | ||||
| President and Chief Executive Officer | ||||
2